b 2  Adrenergic agonists have been widely used to treat patients with asthma. Usually, oral dosage forms of b 2  agonists have been used, but side eŠects such as palpitation and tremor have been reported because of excessive serum levels around Tmax. It is said that circadian variations exist in the manifestation of asthma with maximum incidence of asthma attacks in early morning at around 4 a.m., the so-called morning dip. Chronotherapy for asthma based on circadian rhythm should be more e‹cient and have a lower frequency of side eŠects. Accordingly we developed a transdermal delivery system of the b 2  agonist tulobuterol adapted to the circadian rhythm. The system is designed to administer the appropriate dose of the drug at an optimal time using the so-called Crystal Reservoir System. The superiority of the transdermal formulation of tulobuterol over the current therapy using oral formulations of b 2  stimulants was indicated by its excellent pharmacokinetic proˆle, and conˆrmed by the results of clinical trials. This formulation is theˆrst transdermal chrono-delivery system reported anywhere in the world, and is expected to provide more eŠective and safe treatment of asthma and related diseases not only in adults, but also especially in children.

